Identifying Prognostic Factors in Mycosis Fungoides and Sezary Syndrome
Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients With Advanced Mycosis Fungoides and Sézary Syndrome
This study is trying to find out which factors can help predict survival for patients with advanced mycosis fungoides and Sezary syndrome to improve their care and outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2000 (estimated) |
| Sex | All |
| Sponsor | Stanford University Academic / other |
| Locations | 13 sites (Duarte, California and 12 other locations) |
| Trial ID | NCT02848274 on ClinicalTrials.gov |
What this trial studies
This observational study aims to develop a prognostic index model for mycosis fungoides and Sezary syndrome by collecting standardized clinical data from various institutions. The goal is to identify low- and high-risk groups for survival, which could lead to improved patient care and outcomes. Participants will include patients diagnosed with advanced stages of these conditions within six months of presentation. The study will utilize data from multiple centers to enhance the robustness of the findings.
Who should consider this trial
Good fit: Ideal candidates are patients diagnosed with advanced stage mycosis fungoides or Sezary syndrome within six months of their initial presentation.
Not a fit: Patients with early stage mycosis fungoides or Sezary syndrome, or those diagnosed more than six months prior to presentation, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better risk stratification and personalized treatment plans for patients with mycosis fungoides and Sezary syndrome.
How similar studies have performed: While this approach is focused on a rare disease, similar studies in other hematological malignancies have shown success in developing prognostic models.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria * Diagnosis of advanced stage MF or SS (Stages IIB - IVB) within 6 months of presentation to the participating center * Patients that are expected to have care administered at the participating center or jointly with referring physician(s) where follow-up data would be available Exclusion Criteria * Patients diagnosed with early stage MF/SS (Stages IA-IIA) before progressing to advanced stage * Patients diagnosed with advanced MF/SS more than 6 months prior to initial presentation to the participating center * Exclude one-time consultation type of new patients.
Where this trial is running
Duarte, California and 12 other locations
- City of Hope — Duarte, California, United States (Recruiting)
- Stanford University, School of Medicine — Palo Alto, California, United States (Recruiting)
- University of Iowa — Iowa City, Iowa, United States (Recruiting)
- Hackensack University Medical Center — Hackensack, New Jersey, United States (Recruiting)
- University of Pittsburg — Pittsburgh, Pennsylvania, United States (Recruiting)
- University of Texas Southwestern — Dallas, Texas, United States (Recruiting)
- University of Utah Hospital — Salt Lake City, Utah, United States (Recruiting)
- Hospital Italiano de Buenos Aires — Buenos Aires, Argentina (Recruiting)
- Peter MacCallum Cancer Center, — Melbourne, Australia (Recruiting)
- University of Sao Paulo Medical School — São Paulo, Brazil (Recruiting)
- Peking University First Hospital — Beijing, China (Recruiting)
- The University of Tokyo — Tokyo, Japan (Recruiting)
- University Hospitals Birmingham — Birmingham, United Kingdom (Recruiting)
Study contacts
- Principal investigator: Youn H Kim, MD — Stanford University
- Study coordinator: Tatiana Neal
- Email: tatianan@stanford.edu
- Phone: 650-709-7838
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.